{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-015888","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.783171+00:00","generated_at":"2026-06-17T06:54:10.974524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SANUWAVE reports record FY2022 revenue of $16.7M, restates prior quarterly financials","bullets":["FY2022 revenue $16.7M (+29% YoY); Q4 revenue $5.5M (+32% vs Q3 2022).","GAAP operating loss improved to $9.0M in FY2022 from $14.1M in 2021; Q4 op loss $1.5M.","Restated Q1, Q2, Q3 2022 financials due to material errors in accounting for shares, asset sales, vendor invoices, interest, inventory.","Q1 2023 guidance: revenue growth 14-20% vs Q1 2022; supply constraint alleviated.","New executives added (EVP Sales, VP Commercial Ops, VP Ops); stock now trades on OTCQB."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-015888","json":"https://secwatch.observer/filing/0001140361-23-015888.json","markdown":"https://secwatch.observer/filing/0001140361-23-015888.md","text":"https://secwatch.observer/filing/0001140361-23-015888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123015888/0001140361-23-015888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123015888/brhc10050787_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:54:10.974524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d95649b23179d4ca8714538e5f5aea4b5704635","claim":"SANUWAVE Health, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $5.5 million. Guidance initiated.","evidence_excerpt":"Revenues increased by 32% to $5.5 million for the fourth quarter ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123015888/0001140361-23-015888-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$5.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"da454bca75827d238c29a1a2ae6b5ea96d131720","claim":"SANUWAVE Health, Inc. reported the year ended December 31, 2022 results: revenue $16.7 million. Guidance initiated.","evidence_excerpt":"Revenues increased by 29% to $16.7 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123015888/0001140361-23-015888-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$16.7 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}